Rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) is Buy. Its Reaffirms by B. Riley FBR with $219 Target.

June 27, 2018 - By Ashley Edward

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Corporate Logo

During Q1 2018 the big money sentiment decreased to 1.02. That’s change of 0.07, from 2017Q4’s 1.09. 29 investors sold all, 96 reduced holdings as Jazz Pharmaceuticals plc ratio dropped. 84 rose positions while 44 funds acquired positions. Funds hold 51.95 million shares thus 1.94% less from 2017Q4’s 52.98 million shares.

Hardman Johnston Advsrs Limited Liability Com has 36,460 shs. Schroder Mngmt holds 0.06% or 221,300 shs. Canada Pension Plan Inv Board has 0.01% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 34,971 shs. Aviance Partners Limited Liability Company reported 15,663 shs or 0.71% of all its holdings. Moreover, Amer Century Companies Inc has 0.05% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 341,822 shs. California-based Eqis Cap Management has invested 0.06% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). State Board Of Administration Of Florida Retirement System, a Florida-based fund reported 4,697 shs. Virtu Ltd Llc accumulated 3,097 shs. Aqr Capital Mngmt Ltd Liability has 0.02% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 120,209 shs. The Massachusetts-based Contravisory Invest Mgmt has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). 108,257 were reported by Icon Advisers. Meritage Mgmt stated it has 33,812 shs. Acadian Asset Mgmt Limited Liability reported 30,371 shs stake. 4,300 were accumulated by Thomas White Interest. Clarivest Asset Mngmt Limited Company invested in 2,915 shs or 0.01% of the stock.

Jazz Pharmaceuticals plc registered $5.86 million net activity with 0 insider buys and 23 sales since January 12, 2018. On Monday, April 16 Young Matthew P. sold $109,207 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 700 shs. On Tuesday, May 1 COZADD BRUCE C sold $151,570 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 1,000 shs. WILSON KAREN J sold $604,345 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Tuesday, April 10. On Thursday, March 1 Treacy Paul sold $122,446 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) or 877 shs.

Reiterated Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating.

On Tuesday, 26 June B. Riley FBR have a $219 TP on Jazz Pharmaceuticals (NASDAQ:JAZZ). A upside potential of 25.22 % have this TP. The $10.54 billion market cap company have Buy stock rating shown in a research note.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

In total 11 analysts cover Jazz Pharmaceuticals (NASDAQ:JAZZ). “Buy” rating has 10, “Sell” are 0, while 1 are “Hold”. 91% are bullish. 19 are the (NASDAQ:JAZZ)’s analyst reports since January 2, 2018 according to StockzIntelligence Inc. On Monday, June 25 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given by FBR Capital. On Tuesday, January 30 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by Piper Jaffray. In Thursday, April 12 report Piper Jaffray maintained the stock with “Buy” rating. The company rating was maintained by BMO Capital Markets on Thursday, January 11. In Thursday, May 10 report FBR Capital maintained the stock with “Buy” rating. On Friday, June 1 the firm has “Buy” rating given by RBC Capital Markets. On Wednesday, February 28 the firm has “Outperform” rating by BMO Capital Markets given. On Monday, March 19 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Overweight” rating by Morgan Stanley. On Monday, April 30 the stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given by Cantor Fitzgerald. On Friday, March 9 the firm earned “Buy” rating by FBR Capital.

JAZZ is touching $174.885 during the last trading session, after increased 0.57%.Currently Jazz Pharmaceuticals plc is uptrending after 8.53% change in last June 27, 2017. JAZZ has 127,093 shares volume. The stock underperformed the S&P 500 by 4.04%.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is anticipated to announce earnings on August, 14., RTT reports. Analysts expect change of 66.86 % or $1.15 from previous year’s $1.72 earnings per share compared to current’s $2.87 earnings per share. If $2.87 is reported, JAZZ’s profit will hit $173.02M for 15.23 P/E. After $2.63 EPS report previous quarter, Wall Street now sees 9.13 % EPS growth of Jazz Pharmaceuticals plc.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.The firm is worth $10.54 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.23.95 is the P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

A couple more Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were posted by: Benzinga.com which released on June 21, 2018 “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street”, also Streetinsider.com on June 27, 2018 posted “Jazz Pharmaceuticals (JAZZ) PT Raised to $220 at Cowen; ‘Transitioning Growth Asset'”, the next Prnewswire.com is “Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference” on June 06, 2018. Seekingalpha.com has article titled “Key events next week – healthcare”.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: